Pharma News, 2025

Novavax’s H5N1 avian influenza vaccine candidate shows a robust immune response with 1- and 2-dose intranasal or intramuscular administration for nonhuman primates.

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Would you like a reduction in the prices that you pay for medications? How about a 30% to 40% reduction?

How the FDA Response on UX111 Is Shaping Ultragenyx Pharmaceutical's (RARE) Investment Narrative

Scientists from UC San Francisco and the Gladstone Institutes have made a discovery that could offer new hope to people with Alzheimer’s disease.

People with diabetes are more likely to suffer from depression than people without the condition.

A new study from the Medical University of Vienna shows that high blood pressure on its own—without other health problems like diabetes—can cause early damage to the kidneys.

Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

The WHO's director-general says leaders want self-reliance, with tobacco and alcohol tax rises on the cards to boost domestic revenue.

Scotiabank raised its price target on Apellis Pharmaceuticals to $22.00 from $20.00 on Wednesday, while maintaining a Sector Perform rating following FDA approval of Empaveli (Pegcetacoplan).

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study